Exactech, Inc. (NASDAQ:EXAC) updated its third quarter earnings guidance on Thursday. The company provided earnings per share guidance of $0.19-0.21 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.24. The company issued revenue guidance of $61.4 million (prior: $60.5-62.5 million), compared to the consensus revenue estimate of $61.64 million.

A number of research analysts have issued reports on the company. BidaskClub raised Exactech from a sell rating to a hold rating in a report on Friday, August 18th. Gabelli reissued a buy rating on shares of Exactech in a report on Monday, July 31st.

Exactech, Inc. (NASDAQ EXAC) opened at 33.05 on Friday. The company has a 50 day moving average price of $31.58 and a 200-day moving average price of $29.84. Exactech, Inc. has a 12-month low of $22.20 and a 12-month high of $34.25. The company has a market capitalization of $472.48 million, a PE ratio of 3305.00 and a beta of 1.01.

Exactech (NASDAQ:EXAC) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Exactech had a return on equity of 7.39% and a net margin of 0.30%. The business had revenue of $67.30 million during the quarter, compared to the consensus estimate of $67.75 million. During the same period in the prior year, the company earned $0.31 EPS. Exactech’s revenue for the quarter was up 1.8% on a year-over-year basis. On average, analysts anticipate that Exactech, Inc. will post $1.29 EPS for the current year.

In related news, Director Fern Watts sold 1,013 shares of the company’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $29.04, for a total transaction of $29,417.52. Following the completion of the sale, the director now directly owns 4,727 shares in the company, valued at approximately $137,272.08. The sale was disclosed in a filing with the SEC, which is available through this link. 28.30% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Exactech, Inc. (EXAC) Updates Q3 Earnings Guidance” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/13/exactech-inc-exac-updates-q3-earnings-guidance.html.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Earnings History and Estimates for Exactech (NASDAQ:EXAC)

Receive News & Stock Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related stocks with our FREE daily email newsletter.